Influence of the Degree of Gastric Mucosal Atrophy on the Serum Lipid Levels Before and After the Eradication of Helicobacter pylori Infection

Kyoichi Adachi¹, Tomoko Mishiro¹, Eiko Okimoto¹ and Yoshikazu Kinoshita²

Abstract:
Objective To clarify the influence of the degree of gastric mucosal atrophy on the serum lipid levels before and after the eradication of Helicobacter pylori infection.
Methods The subjects were individuals who underwent an annual detailed medical checkup. Serum anti-H. pylori IgG antibody detection and upper endoscopic examinations were performed in all subjects. Gastric mucosal atrophy was evaluated by the classification of Kimura and Takemoto. The serum levels of total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDLC), LDLC/HDL-C ratio, and triglycerides were compared among the different degrees of gastric mucosal atrophy in H. pylori-positive subjects. In addition, changes in those serum lipid levels during a two-year period were compared among H. pylori post-eradication cases that showed different degrees of gastric mucosal atrophy prior to eradication.
Results In subjects with higher degrees of gastric mucosal atrophy, the serum levels of total cholesterol, LDLC, and triglycerides were elevated. Furthermore, the LDLC/HDL-C ratio in subjects with moderate and severe grades of gastric mucosal atrophy was significantly higher than in subjects with mild atrophy. In subjects with higher degrees of gastric mucosal atrophy, the serum level of LDLC and the LDLC/HDL-C ratio were decreased following eradication of H. pylori.
Conclusion Lipid metabolism is influenced by the degree of gastric mucosal atrophy present before the eradication of H. pylori, and the favorable effects of such eradication are significant in patients with higher degrees of atrophy.
Key words: lipid metabolism, Helicobacter pylori, eradication, gastric mucosal atrophy

Introduction

Lipid metabolism and arteriosclerosis progression have been repeatedly demonstrated to be affected by several different types of bacterial and viral infections, such as Chlamydia and cytomegalovirus (1-3). Helicobacter pylori infection has also been reported to worsen lipid metabolism (4-9), and its eradication is known to have a favorable effect on lipid metabolism (10-15).

Infection with H. pylori typically occurs during childhood, and a long-term persistent H. pylori infection can cause chronic gastritis, which is closely associated with the development of atrophic gastritis (16-18). Therefore, H. pylori-induced changes in lipid metabolism may be influenced by the degree of gastric mucosal atrophy, since the duration of continuous H. pylori infection and grade of gastric mucosal inflammation have effects on the degree of gastric mucosal atrophy. Gastric mucosal inflammation has also been demonstrated to affect the production of pro-inflammatory cytokines, which is also correlated with lipid metabolism (19). However, the relationship between the de-

¹Health Center, Shimane Environment and Health Public Corporation, Japan and ²Second Department of Internal Medicine, Shimane University Faculty of Medicine, Japan
Received: February 22, 2018; Accepted: April 1, 2018; Advance Publication by J-STAGE: June 6, 2018
Correspondence to Dr. Kyoichi Adachi, adachi@kanhokou.or.jp
gree of gastric mucosal atrophy and lipid metabolism has not been clarified. In addition, no known investigations have been conducted to determine whether or not the degree of gastric mucosal atrophy prior to \textit{H. pylori} eradication influences the changes in lipid metabolism following successful eradication.

The present study was performed to clarify the influence of the degree of gastric mucosal atrophy on the serum lipid levels before and after the eradication of \textit{H. pylori}.

**Materials and Methods**

**Study 1**

The subjects in Study 1 were individuals who visited the Health Center of Shimane Environment and Health Public Corporation for an annual detailed medical checkup between April 2014 and March 2015. The majority were socially active and productive and considered to be socioeconomically middle class. A precise medical history was obtained by a trained public health nurse from each subject. Those taking medication for hyperlipidemia were excluded in order to eliminate the influence of medication on serum lipid parameters, as were subjects with a history of \textit{H. pylori} eradication. Each subject underwent an upper endoscopic examination performed by a licensed experienced endoscopist. Gastric mucosal atrophy was evaluated based on the endoscopic findings using the classification of Kimura and Takemoto, in which gastric mucosal atrophy is classified into six groups (C1, C2, C3, O1, O2, O3) (20). This classification has been proven to correlate well with the histological features of atrophy. For the study, C1-C2 was defined as mild, C3-O1 as moderate, and O2-O3 as severe gastric mucosal atrophy.

Serum anti-\textit{H. pylori} IgG antibody detection was performed using a SphereLight \textit{H. pylori} antibody J kit (Wako Pure Chemical Industries, Osaka, Japan) (21). The antibody titer was automatically measured using a chemiluminescent enzyme immunoassay, and a value of ≥4.0 U/mL was defined as positive, according to the manufacturer’s instructions. Subjects with endoscopic gastric mucosal atrophy of C2-O3 and negative in anti-\textit{H. pylori} IgG antibody test findings were excluded from the study, as they might have had a post-eradication status even though they had not previously undergone eradication therapy or been positive for \textit{H. pylori} infection (21).

All subjects underwent a physical examination, and hematological and biochemical blood tests of samples obtained after an overnight fast were performed at the laboratory of Shimane Environment and Health Public Corporation. Factors investigated in this study included the gender, age, body mass index (BMI), smoking habit, and drinking habit (>50 mL alcohol/day), as well as the serum levels of total cholesterol, high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), and triglycerides. The serum total cholesterol, HDL, LDL, and triglyceride levels, as well as the LDL/HDL ratio (22-25) were compared between the \textit{H. pylori}-positive and -negative subjects before and after adjusting for covariate factors (gender, age, BMI, smoking, drinking) using an analysis of covariance method. In addition, factors were compared among \textit{H. pylori}-positive subjects with different degrees of gastric mucosal atrophy.

**Study 2**

Study 2 investigated the changes in the serum lipid levels in subjects from Study 1 who revisited the same medical center between April 2016 and March 2017 for another annual examination. Therefore, all Study 2 subjects underwent biochemical blood tests for serum lipids twice with a two-year interval. Those who received medical care for hyperlipidemia during those two years were excluded.

The history of eradication therapy for \textit{H. pylori} and successful eradication prior to the second visit were determined based on a precise medical history of each subject obtained by a trained public health nurse. Nearly all of the \textit{H. pylori}-positive subjects still had not undergone eradication therapy for \textit{H. pylori}, even though we advised all who were found to be positive for \textit{H. pylori} infection at the first examination to undergo eradication therapy. Successful eradication of \textit{H. pylori} was determined based on the results of a urea breath or stool antigen test. Those without successful eradication were included in the group positive for \textit{H. pylori} infection, even if they had received eradication therapy. When eradication therapy was determined to be not successful, we recommended that the subject undergo an \textit{H. pylori} stool antigen test at our institution. Successful eradication was also confirmed by changes in the gastric mucosal findings obtained in an upper GI endoscopic examination, which was performed for all subjects.

The gastric mucosal findings used to determine successful eradication included the presence of map-like redness or depressed patchy redness, as well as absence of diffuse redness, mucosal swelling, sticky mucous, and enlarged folds (26-29). When the gastric mucosal findings were not changed in comparison with those prior to eradication therapy, we diagnosed the subject as positive for \textit{H. pylori} infection, regardless of the history of eradication therapy. All endoscopic images for each subject were simultaneously reviewed by three licensed endoscopists who performed the diagnosis of each endoscopic finding. When there were inconsistencies in judgment of the endoscopic images among the endoscopists, the final diagnosis was decided by the lead endoscopist (K.A.).

Changes in the serum levels of total cholesterol, HDL, and LDL, as well as the LDL/HDL ratio and triglycerides during the two-year period were analyzed and compared among the \textit{H. pylori}-positive, \textit{H. pylori}-negative, and \textit{H. pylori}-eradicated groups. Those parameters were also analyzed in post-eradicated cases with different degrees of gastric mucosal atrophy shown prior to undergoing eradication.
Study 1

There were 729 subjects (467 men, 262 women; mean age 51.1 years) in Study 1. None had a history of eradication for *H. pylori* or medical care for hyperlipidemia. The number of subjects with and without *H. pylori* infection was 433 and 296, respectively. Those with infection were older than those without (Table 1). The serum level of HDLC in the *H. pylori*-positive group was significantly lower than in the *H. pylori*-negative group, even after adjusting for covariate factors. In addition, the serum levels of total cholesterol and triglycerides in the *H. pylori*-positive subjects tended to be higher than in the *H. pylori*-negative group. The LDLC/HDLC ratio was also higher in the *H. pylori*-positive group than in the *H. pylori*-negative group. The analysis after dividing the study subjects by gender also showed that the serum level of HDLC was lower and the LDLC/HDLC ratio higher in the *H. pylori*-positive group than in the *H. pylori*-negative group (data was not shown).

When the serum lipid levels were compared among the different degrees of gastric mucosal atrophy in *H. pylori*-positive cases, they were found to be significantly influenced by the degree of atrophy. In subjects with a higher degree of gastric mucosal atrophy, the levels of total cholesterol, LDLC, and triglycerides were high, while the level of HDLC was low. In addition, the LDLC/HDLC ratios in subjects with moderate and severe grades of gastric mucosal atrophy were significantly higher than in those with a mild grade, even after adjusting for covariate factors.

Table 1. *Helicobacter pylori* Infection Status and Serum Lipid Parameters at First Visit (2014).

| H. pylori status | Negative | Positive |
|------------------|----------|----------|
|                  | Total    | Mild atrophy | Moderate atrophy | Severe atrophy |
| Gender (male/female) | 184/112 | 283/150 | 100/48 | 113/74 | 70/28 |
| Age in years     | 48.4±0.5 | 50.1±0.8 | 52.4±0.6 | 58.7±0.9 | 58.7±0.9 |
| BMI              | 22.6±0.2 | 22.8±0.3 | 22.8±0.2 | 22.7±0.3 | 22.7±0.3 |
| Habitual smoking | 48 (16.2%) | 99 (23.6%) | 35 (9.3%) | 36 (19.3%) | 28 (28.6%) |
| Habitual drinking | 165 (55.7%) | 243 (56.1%) | 83 (56.1%) | 101 (54.0%) | 59 (60.2%) |
| T cho. (mg/dL)   | 207.9±1.8 | 201.4±2.6 | 210.4±2.4 | 213.7±3.6 | 213.7±3.6 |
| HDLC (mg/dL)     | 68.1±1.1 | 65.0±1.3 | 63.2±1.2 | 63.6±1.9 | 63.6±1.9 |
| LDLC (mg/dL)     | 128.0±1.7 | 123.1±2.2 | 134.0±2.9 | 132.7±3.4 | 132.7±3.4 |
| LDLC/HDLC ratio  | 2.04±0.05 | 2.02±0.06 | 2.27±0.06 | 2.29±0.10 | 2.29±0.10 |
| TG (mg/dL)       | 100.7±3.7 | 109.3±5.6 | 109.2±4.9 | 136.6±15.8 | 136.6±15.8 |

Data was expressed by means±SE. Gastric mucosal atrophy was evaluated using the classification of Kimura and Takemoto (C1-C2: mild, C3-O1: moderate, O2-O3: severe gastric mucosal atrophy). Numbers in parenthesis indicate adjusted value for covariate factors (gender, age, BMI, smoking, drinking). *p<0.05 in comparison with *H. pylori*-negative subjects. +p<0.05 in comparison with the subjects with mild gastric mucosal atrophy. **p<0.05 in comparison with the subjects with moderate gastric mucosal atrophy. BMI: body mass index, T cho.: total cholesterol, HDLC: HDL-cholesterol, LDLC: LDL-cholesterol, TG: triglycerides.
in the H. pylori-negative and -positive, and post-eradication subjects at the second visit as compared to those at the first visit, though a significant increase was only observed with the HDLC level in subjects who underwent eradication. The level of LDL-C in the serum and the LDL-C/HDL-C ratio were increased after eradication in all groups. The values of TG and the TG/HDL-C ratio were decreased in the post-eradication subjects (Table 2).

When changes in the serum lipid levels were analyzed in post-eradication subjects divided based on the degree of gastric mucosal atrophy, there were significant differences among the groups. The serum level of HDLC showed a mild increase in all groups. The values of LDL-C and the LDL-C/HDL-C ratio were increased after H. pylori eradication in subjects with mild gastric mucosal atrophy but were decreased in subjects with greater degrees of gastric mucosal atrophy. In contrast, there was no obvious trend regarding the changes in the serum triglyceride levels in the subjects regardless of the degree of gastric mucosal atrophy (Table 3). The same differences in the changes in serum lipid parameters after eradication for H. pylori between the different degrees of gastric mucosal atrophy were observed after analyzing by dividing the study subjects by gender (Table 4).

### Discussion

Bacterial and viral infections have been repeatedly demonstrated to be associated with increased serum levels of fibrinogen and lipids, well-known risk factors for cardiovascular disease (1–3). H. pylori infection is known to be related to the onset of several gastrointestinal diseases, including gastritis, peptic ulcer disease, gastric cancer, and low-grade B cell lymphoma in gastric mucosa-associated-lymphoid tissue (17, 18, 30–32). Furthermore, persistent low-grade inflammation induced by H. pylori infection was reported to produce pro-inflammatory cytokines, such as C reactive protein, and interleukin (IL)-6 and IL-8, which have major effects on lipid metabolism and arteriosclerosis progression (19). Indeed, serum lipid metabolism has been demonstrated to be influenced by H. pylori infection (4–9). In addition, the successful eradication of H. pylori infection has been shown to have a favorable effect on lipid metabolism (10–15). The degree of gastric mucosal atrophy is influ-

### Table 2. Helicobacter pylori Infection Status and Time-course Changes of Serum Lipid Parameters.

| H. pylori status at 2016 | Negative group | Positive group | Eradicated group |
|-------------------------|----------------|----------------|-----------------|
| Gender (male/female)    | 113/61         | 49/15          | 134/65          |
| Age in years at 2014    | 49.4±0.6       | 50.8±1.2       | 53.2±0.6        |
| Habitual smoking        | 27 (15.5%)     | 22 (34.4%)     | 35 (17.6%)      |
| Habitual drinking       | 103 (59.2%)    | 37 (57.8%)     | 129 (64.8%)     |
| BMI (2014/2016)         | 22.5±0.2/22.6±0.2* | 23.0±0.4/23.1±0.4 | 22.6±0.2/22.6±0.2 |
| T cho. (mg/dL) (2014/2016) | 212.2±2.4/214.1±2.4 | 206.2±4.0/211.2±3.5 | 208.7±2.2/211.7±2.2 |
| HDLC (mg/dL) (2014/2016) | 68.5±1.4/69.0±1.1 | 61.4±1.8/62.2±1.9 | 64.8±1.2/66.1±1.3* |
| LDLC (mg/dL) (2014/2016) | 131.8±2.3/131.8±2.3 | 129.2±3.6/132.1±3.4 | 131.1±2.1/130.2±2.0 |
| LDLC/HDL-C ratio (2014/2016) | 2.09±0.062/2.083±0.064 | 2.240±0.098/2.292±0.108 | 2.178±0.058/2.132±0.057 |
| TG (mg/dL) (2014/2016)  | 100.5±4.5/102.5±5.7 | 122.3±10.5/118.7±8.8 | 110.1±7.8/111.3±8.3 |

Data was expressed by mean±SE. *p<0.05 in comparison with H. pylori-positive subjects. p<0.05 in comparison with the data of 2014. BMI: body mass index, T cho.: total cholesterol, HDLC: HDL-cholesterol, LDLC: LDL-cholesterol, TG: triglycerides.

### Table 3. Degree of Gastric Mucosal Atrophy and Time-course Changes of Serum Lipid Parameters in Eradicated Cases.

| Gastric mucosal atrophy | Mild | Moderate | Severe |
|-------------------------|------|----------|--------|
| Gender (male/female)    | 42/19 | 55/39    | 37/7   |
| Age in years at 2014    | 50.8±1.1 | 52.5±0.8 | 58.3±1.2 |
| Habitual smoking        | 6 (9.8%) | 18 (19.1%) | 11 (25.0%) |
| Habitual drinking       | 43 (70.5%) | 57 (60.6%) | 29 (65.9%) |
| BMI(2014/2016)          | 22.5±0.3/22.6±0.4 | 22.6±0.3/22.7±0.3* | 22.7±0.4/22.5±0.4 |
| T cho. (mg/dL) (2014/2016) | 201.0±3.7/209.6±3.8* | 212.0±3.1/214.6±3.0 | 212.4±5.4/208.6±5.3 |
| HDLC (mg/dL) (2014/2016) | 67.4±2.1/68.6±2.0 | 64.2±1.8/65.5±2.0 | 62.0±2.3/63.7±2.7 |
| LDLC (mg/dL) (2014/2016) | 122.3±3.2/127.1±3.3 | 136.3±3.0/135.3±2.8 | 132.2±5.2/123.7±4.9* |
| LDLC/HDL-C ratio (2014/2016) | 1.919±0.078/1.961±0.083 | 2.285±0.082/2.236±0.078 | 2.309±0.152/2.146±0.160* |
| TG (mg/dL) (2014/2016)  | 97.6±6.5/107.0±14.6 | 102.3±5.1/97.2±4.1 | 144.0±32.0/147.7±29.9 |

Data was expressed by mean±SD. Gastric mucosal atrophy was evaluated using the classification of Kimura and Takemoto at 2014 (before eradication) (C1-C2: mild, C3-O1: moderate, O2-O3: severe gastric mucosal atrophy). *p<0.05 in comparison with the data of 2014. BMI: body mass index, T cho.: total cholesterol, HDLC: HDL-cholesterol, LDLC: LDL-cholesterol, TG: triglycerides.
enced by the duration of \textit{H. pylori} infection as well as the grade of gastric mucosal inflammation (20). Therefore, gastric mucosal atrophy degree may be related to lipid metabolism and those serum parameters.

In the present study, the level of HDLC in serum in the \textit{H. pylori}-positive group was significantly lower than in the \textit{H. pylori}-negative group, which has also been shown in previous studies. Furthermore, the level of HDLC in our \textit{H. pylori}-positive subjects with a higher degree of gastric mucosal atrophy was decreased compared with those with a mild degree of atrophy. As a result, LDLCh/HDLCh ratio was high in the \textit{H. pylori}-positive subjects, especially those with a higher degree of gastric mucosal atrophy. In addition, other serum lipid levels were worse in subjects with a higher degree of gastric mucosal atrophy. Since the initial \textit{H. pylori} infection typically occurs during childhood (16, 18), the period of infection in individuals with a higher degree of gastric mucosal atrophy is considered to be longer than in those with a milder degree, indicating that a long-term \textit{H. pylori} infection is associated with severely worse serum lipid metabolism. In the present study, the influence of a higher degree of gastric mucosal atrophy on serum lipid metabolism was significant, even after adjusting for covariate factors. Therefore, the degree of gastric mucosal atrophy is considered to be an important factor that influences the lipid metabolism.

Several investigators have reported that successful eradication of \textit{H. pylori} favorably affects lipid metabolism (10-15). Our analysis of the changes in the serum lipid level after eradication also showed that the level of LDLCh in serum as well as the LDLCh/HDLCh ratio tended to increase in subjects continuously positive for \textit{H. pylori}, whereas those values were decreased following eradication. The most interesting observation in our study was that the degree of gastric mucosal atrophy prior to eradication had effects on the change in the serum lipid level following successful eradication. The level of LDLCh in the serum and the LDLCh/HDLCh ratio were both increased after eradication of \textit{H. pylori} in subjects with a mild degree of gastric mucosal atrophy, whereas those values were decreased after eradication in subjects with either a moderate or severe degree of gastric mucosal atrophy. Therefore, the favorable effect on lipid metabolism following eradication in subjects with \textit{H. pylori} infection is considered to be high in cases with a higher degree of gastric mucosal atrophy. The present findings fail to explain why the degree of gastric mucosal atrophy prior to eradication of \textit{H. pylori} is related to the change in the serum lipid level after eradication. Since the level of serum lipids prior to eradication was worse in cases with a higher degree of gastric mucosal atrophy than in those with a milder degree of atrophy, the effect of \textit{H. pylori} infection on lipid metabolism may be greater in individuals with a higher degree of gastric mucosal atrophy than in those with a milder degree. The changes in the serum levels of pro-inflammatory cytokine and ghrelin after eradication for \textit{H. pylori} might have influenced the difference in the lipid metabolism among the subjects with different degrees of gastric mucosal atrophy, since those have been shown to be related to not only the degree of gastric mucosal inflammation and atrophy but also the lipid metabolism and dietary habits (19, 33, 34). Further studies are needed to clarify why the degree of gastric mucosal atrophy influenced lipid metabolism before and after the eradication of \textit{H. pylori} infection.

Several limitations associated with the present study warrant mention. First, the subjects were not representative of the general population, as they were individuals who voluntarily visited our medical center for annual checkups, with the numbers of young and elderly subjects relatively few. Furthermore, we did not investigate the changes in the upper gastrointestinal symptoms and dietary habits during the two-year interval, although the successful eradication of \textit{H. pylori} is well-known to induce changes in several upper gastrointestinal symptoms. Changes in the dietary and lipid intake might have affected the time-course of changes in the

Table 4. Degree of Gastric Mucosal Atrophy and Time-course Changes of Serum Lipid Parameters in Eradicated Male and Female Cases.

| Gastric mucosal atrophy   | Mild               | Moderate          | Severe             |
|--------------------------|--------------------|-------------------|--------------------|
| **BMI (2014/2016)**      | Male               | Female            | Male               | Female            |
|                          | 23.0±0.4/23.0±0.4  | 23.5±0.4/23.7±0.4 | 23.2±0.4/23.1±0.5  |
|                          | 21.4±0.6/21.5±0.7  | 21.2±0.5/21.4±0.5 | 19.9±0.8/19.7±0.8  |
| **T cho. (mg/dL) (2014/2016)**  | Male               | Female            | Male               | Female            |
|                          | 198.5±4.2/209.8±3.7  | 208.1±4.2/210.3±3.9  | 211.6±6.3/207.2±5.9  |
|                          | 206.5±7.2/209.2±6.7  | 217.5±4.5/220.2±6.4  | 216.6±8.4/215.9±11.4  |
| **HDLC (mg/dL) (2014/2016)**  | Male               | Female            | Male               | Female            |
|                          | 64.6±2.5/66.4±2.5  | 58.7±2.0/59.9±2.0  | 57.9±2.1/59.6±2.6  |
|                          | 73.7±3.1/73.7±3.2  | 72.0±2.9/73.4±3.5  | 83.3±3.4/85.4±3.6  |
| **LDLC (mg/dL) (2014/2016)**  | Male               | Female            | Male               | Female            |
|                          | 120.5±3.7/127.3±4.1  | 136.4±3.8/135.6±3.4  | 133.5±6.0/123.9±5.6  |
|                          | 126.1±6.1/126.7±5.6  | 136.1±4.8/134.9±4.8  | 125.1±6.1/122.9±8.9  |
| **LDLC/HDLCh ratio (2014/2016)**  | Male               | Female            | Male               | Female            |
|                          | 1.990±0.100/2.044±0.109  | 2.459±0.103/2.395±0.095  | 2.462±0.170/2.281±0.182  |
|                          | 1.762±0.112/1.776±0.107  | 2.040±0.125/2.012±0.124  | 1.500±0.038/1.434±0.088  |
| **TG (mg/dL) (2014/2016)**  | Male               | Female            | Male               | Female            |
|                          | 110.8±8.4/122.6±20.5  | 117.6±6.9/105.4±5.5  | 161.1±37.5/165.2±34.9  |
|                          | 68.3±5.1/72.5±8.1  | 80.8±6.0/85.6±5.9  | 54.1±5.4/55.3±4.3  |

Data was expressed by mean±SE. Gastric mucosal atrophy was evaluated using the classification of Kimura and Takemoto at 2014 (before eradication) (C1-C2: mild, C3-O1: moderate, O2-O3: severe gastric mucosal atrophy). 

References:
1. Intern Med 57: 3067-3073, 2018 DOI: 10.2169/internalmedicine.1074-18
serum lipid parameters in the subjects. In addition, the two-year follow-up period was too short to investigate the progression of arteriosclerosis or occurrence of cardiovascular events. Therefore, additional large-scale long-term prospective studies are needed in order to confirm the influence of the degree of gastric mucosal atrophy on lipid metabolism before and after the eradication of *H. pylori*.

In conclusion, lipid metabolism before and after *H. pylori* eradication are influenced by the degree of gastric mucosal atrophy present prior to performing eradication. In addition, the favorable effect of eradication of *H. pylori* on the lipid metabolism was particularly significant in subjects with a higher degree of atrophy.

The authors state that they have no Conflict of Interest (COI).

Acknowledgement

We wish to thank Ms. Yoko Komori, Ms. Kiyoe Kawase, Ms. Yuki Funaki, Ms. Noriko Yamauchi and Mr. Takahiro Hatanaka in Shimane Environment and Health Public Corporation, and Ms. Rika Tohma and Ms. Keiko Masuzaki in Second Department of Internal Medicine, Shimane University Faculty of Medicine for their technical support.

References

1. Rubin L. Serum lipoproteins in infectious mononucleosis. Am J Med 17: 521-527, 1954.
2. Alvarez C, Ramos A. Lipids, lipoproteins, and apoproteins in serum during infection. Clin Chem 32: 142-145, 1986.
3. Laurila A, Bloigu A, Näyhä S, Hassi J, Leinonen M, Saikku P. *Chlamydia pneumoniae* antibodies and serum lipids in Finnish men: cross sectional study. BMJ 314: 1456-1457, 1997.
4. Patel P, Mendall MA, Carrington D, et al. Association of *Helicobacter pylori* and *Chlamydia pneumoniae* infections with coronary heart disease and cardiovascular risk factors. BMJ 311: 711-714, 1995.
5. Niemelä S, Karttunen T, Korhonen T, et al. Could *Helicobacter pylori* infection increase the risk of coronary heart disease by modifying serum lipid concentrations? Heart 75: 573-575, 1996.
6. Laurila A, Bloigu A, Näyhä S, Hassi J, Leinonen M, Saikku P. Association of *Helicobacter pylori* infection with elevated serum lipids. Atherosclerosis 142: 207-210, 1999.
7. Takashima T, Adachi K, Kawamura A, et al. Cardiovascular risk factors in subjects with *Helicobacter pylori* infection. Helicobacter 7: 86-90, 2002.
8. Satoh H, Saijo Y, Yoshioka E, Tsutsui H. *Helicobacter pylori* infection is a significant risk for modified lipid profile in Japanese male subjects. J Atheroscler Thromb 17: 1041-1048, 2010.
9. Kim HL, Jeon HH, Park JY, Choi JM, Kang JS, Min KW. *Helicobacter pylori* infection is associated with elevated low density lipoprotein cholesterol levels in elderly Koreans. J Korean Med Sci 26: 654-658, 2011.
10. Ando T, Minami M, Ishiguro K, et al. Changes in biochemical parameters related to atherosclerosis after *Helicobacter pylori* eradication. Aliment Pharmacol Ther 24 (Suppl 4): 58-64, 2006.
11. Nam SY, Ryu KH, Park BJ, Park S. Effects of *Helicobacter pylori* infection and its eradication on lipid profiles and cardiovascular diseases. Helicobacter 20: 125-132, 2015.
12. Chen TP, Hung HF, Chen MK, et al. *Helicobacter pylori* infection is positively associated with metabolic syndrome in Taiwanese adults: a cross-sectional study. Helicobacter 20: 184-191, 2015.
13. Furuta T, Shirai N, Xiao F, Takashima M, Hanai H. Effect of *Helicobacter pylori* infection and its eradication on nutrition. Aliment Pharmacol Ther 16: 799-806, 2002.
14. Franceschi F, Annalisa T, Teresa DR, et al. Role of *Helicobacter pylori* infection on nutrition and metabolism. World J Gastroenterol 20: 12809-12817, 2014.
15. Adachi K, Mikiho T, Todo T, et al. Effects of *Helicobacter pylori* eradication on serum lipid levels. J Clin Biochem Nutr (in press).
16. Graham DY, Malaty HM, Evans DG, Evans DJ Jr, Klein PD, Adam E. Epidemiology of *Helicobacter pylori* in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology 100: 1495-1501, 1991.
17. Parsonnet J, Friedman GD, Vandersteen DP, et al. *Helicobacter pylori* infection and the risk of gastric carcinoma. N Engl J Med 325: 1127-1131, 1991.
18. Asaka M, Kato M, Sakamoto N. Roadmap to eliminate gastric cancer with *Helicobacter pylori* eradication and consecutive surveillance in Japan. J Gastroenterol 49: 1-8, 2014.
19. Buzás GM. Metabolic consequences of *Helicobacter pylori* infection and eradication. World J Gastroenterol 20: 5226-5234, 2014.
20. Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 1: 87-97, 1969.
21. Adachi K, Mikiho T, Tanaka S, Kinoshita Y. Analysis of negative result in serum anti-*H. pylori* IgG antibody test in cases with gastric mucosal atrophy. J Clin Biochem Nutr 59: 145-148, 2016.
22. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297: 499-508, 2007.
23. Kastelein JJ, van der Steeg WA, Holme I, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin therapy. Circulation 117: 3002-3009, 2008.
24. Amorencio P, Goldstein LB, Callahan A 3rd, et al. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Atherosclerosis 204: 515-520, 2009.
25. Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E. Prognostic utility of apoB/Al total cholesterol/HDL non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol 29: 424-430, 2009.
26. Watanabe K, Nagata N, Nakashima R, et al. Predictive findings for *Helicobacter pylori*-uninfected, -infected and -eradicated gastric mucosa: validation study. World J Gastroenterol 19: 4374-4379, 2013.
27. Kato T, Yagi N, Kamada T, et al. Diagnosis of *Helicobacter pylori* infection in gastric mucosa by endoscopic features: a multicenter prospective study. Dig Endosc 25: 508-518, 2013.
28. Kato M, Terao S, Adachi K, et al. Changes in endoscopic findings of gastritis after cure of *H. pylori* infection: multicenter prospective trial. Dig Endosc 25: 264-273, 2013.
29. Kamada T, Haruma K, Inoue K, Shiotani A. *Helicobacter pylori* infection and endoscopic gastritis -Kyoto classification of gastritis. Nihon Shokakibyo Gakkai Zasshi (Jpn J Gastro-enterol) 209: 993, 2015 (in Japanese, Abstract in English).
30. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1: 1311-1314, 1984.
31. Graham DY. Treatment of peptic ulcers caused by *Helicobacter pylori*. N Engl J Med 328: 349-350, 1993.
32. Isaacson PG, Spencer J. Is gastric lymphoma an infectious disease? Hum Pathol 24: 569-570, 1993.
33. Osawa H, Nakazato M, Date Y, et al. Impaired production of gastric ghrelin in chronic gastritis associated with *Helicobacter pylori*.
J Clin Endocrinol Metab 90: 10-16, 2005.

34. Kawashima J, Ohno S, Sakurada T, et al. Circulating acylated ghrelin level decreases in accordance with the extent of atrophic gastritis. J Gastroenterol 44: 1046-1054, 2009.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).